Literature DB >> 15452209

Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene.

Xiaomin Zhao1, Margaret Rush, Stefan Schwartz.   

Abstract

We have previously identified cis-acting RNA sequences in the human papillomavirus type 16 (HPV-16) L1 coding region which inhibit expression of L1 from eukaryotic expression plasmids. Here we have determined the function of one of these RNA elements, and we provide evidence that this RNA element is a splicing silencer which suppresses the use of the 3' splice site located immediately upstream of the L1 AUG. We also show that this splice site is inefficiently utilized as a result of a suboptimal polypyrimidine tract. Introduction of point mutations in the L1 coding region that altered the RNA sequence without affecting the L1 protein sequence resulted in the inactivation of the splicing silencer and induced splicing to the L1 3' splice site. These mutations also prevented the interaction of the RNA silencer with a 35-kDa cellular protein identified here as hnRNP A1. The splicing silencer in L1 inhibits splicing in vitro, and splicing can be restored by the addition of RNAs containing an hnRNP A1 binding site to the reaction, demonstrating that hnRNP A1 inhibits splicing of the late HPV-16 mRNAs through the splicing silencer sequence. While we show that one role of the splicing silencer is to determine the ratio between partially spliced L2/L1 mRNAs and spliced L1 mRNAs, we also demonstrate that it inhibits splicing from the major 5' splice site in the early region to the L1 3' splice site, thereby playing an essential role in preventing late gene expression at an early stage of the viral life cycle. We speculate that the activity of the splicing silencer and possibly the concentration of hnRNP A1 in the HPV-16-infected cell determines the ability of the virus to establish a persistent infection which remains undetected by the host immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452209      PMCID: PMC521837          DOI: 10.1128/JVI.78.20.10888-10905.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells.

Authors:  Brian Collier; Daniel Oberg; Xiaomin Zhao; Stefan Schwartz
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element.

Authors:  T O Tange; C K Damgaard; S Guth; J Valcárcel; J Kjems
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

Review 3.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

4.  The Rev protein of human immunodeficiency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3' untranslated region.

Authors:  W Tan; S Schwartz
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element.

Authors:  P S Bilodeau; J K Domsic; A Mayeda; A R Krainer; C M Stoltzfus
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.

Authors:  C Leder; J A Kleinschmidt; C Wiethe; M Müller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins.

Authors:  J Zhu; A Mayeda; A R Krainer
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

8.  The human papillomavirus type 31 late 3' untranslated region contains a complex bipartite negative regulatory element.

Authors:  Sarah A Cumming; Claire E Repellin; Maria McPhillips; Jonathan C Radford; J Barklie Clements; Sheila V Graham
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

9.  Heterogeneous nuclear ribonucleoprotein C binds exclusively to the functionally important UUUUU-motifs in the human papillomavirus type-1 AU-rich inhibitory element.

Authors:  M Sokolowski; S Schwartz
Journal:  Virus Res       Date:  2001-03       Impact factor: 3.303

10.  Life cycle heterogeneity in animal models of human papillomavirus-associated disease.

Authors:  Woei Ling Peh; Kate Middleton; Neil Christensen; Philip Nicholls; Kiyofumi Egawa; Karl Sotlar; Janet Brandsma; Alan Percival; Jon Lewis; Wen Jun Liu; John Doorbar
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more
  41 in total

1.  Heterogeneous Nuclear Ribonucleoprotein C Proteins Interact with the Human Papillomavirus Type 16 (HPV16) Early 3'-Untranslated Region and Alleviate Suppression of HPV16 Late L1 mRNA Splicing.

Authors:  Soniya Dhanjal; Naoko Kajitani; Jacob Glahder; Ann-Kristin Mossberg; Cecilia Johansson; Stefan Schwartz
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

2.  Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells.

Authors:  Seiichiro Mori; Saori Ozaki; Toshiharu Yasugi; Hiroyuki Yoshikawa; Yuji Taketani; Tadahito Kanda
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

Review 3.  Papillomavirus genome structure, expression, and post-transcriptional regulation.

Authors:  Zhi-Ming Zheng; Carl C Baker
Journal:  Front Biosci       Date:  2006-09-01

4.  Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer.

Authors:  Karsten Bork Nielsen; Suzette Sørensen; Luca Cartegni; Thomas Juhl Corydon; Thomas Koed Doktor; Lisbeth Dahl Schroeder; Line Sinnathamby Reinert; Orly Elpeleg; Adrian R Krainer; Niels Gregersen; Jørgen Kjems; Brage Storstein Andresen
Journal:  Am J Hum Genet       Date:  2007-01-18       Impact factor: 11.025

Review 5.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

6.  A downstream polyadenylation element in human papillomavirus type 16 L2 encodes multiple GGG motifs and interacts with hnRNP H.

Authors:  Daniel Oberg; Joanna Fay; Helen Lambkin; Stefan Schwartz
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression.

Authors:  Margaret Rush; Xiaomin Zhao; Stefan Schwartz
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.

Authors:  Michael Berg; Julie Difatta; Egbert Hoiczyk; Richard Schlegel; Gary Ketner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

9.  A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein.

Authors:  Xiaomin Zhao; Daniel Oberg; Margaret Rush; Joanna Fay; Helen Lambkin; Stefan Schwartz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 10.  Regulation of human papillomavirus gene expression by splicing and polyadenylation.

Authors:  Cecilia Johansson; Stefan Schwartz
Journal:  Nat Rev Microbiol       Date:  2013-03-11       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.